EB-203 for Neovascular Age-related Macular Degeneration

Inclusion Criteria: 1. Adults aged 50 years or older 2. Subjects with a best corrected visual acuity (BCVA) score between 25 and 73, measured by the Early Treatment of Diabetic Retinopathy Study(ETDRS) chart, at a distance of 4 m during the screening (equivalent to 20/40 to 20/320 in the Snellen chart) 3. Subjects who voluntarily signed the informed consent form (ICF) after receiving the information on this study Exclusion Criteria: 1. Subjects with confirmed nAMD requiring standard treatment in both eyes (however, dry AMD in the non-study eye may be enrolled) 2. Subjects who have received ocular or systemic treatment, such as photodynamic therapy (PDT) or laser photocoagulation, or have undergone a surgical operation for nAMD (however, health functional foods, vitamin supplements, etc., are excluded) 3. Subjects whose study eye has been treated with anti-vascular endothelial growth factor (anti-VEGF) drugs (e.g. ranibizumab, bevacizumab, aflibercept, etc.) or a combination therapy for the treatment of nAMD prior to screening 4. Subjects who have received intravitreal treatment using steroids 5. Subjects who have a subretinal hemorrhage in ≥ 50% of the total lesion area or who have a hemorrhage in the subfoveal region of the study eye and in whom the hemorrhage area is ≥ 1 optic disk area 6. Subjects with vitreous hemorrhage in the study eye 7. Subjects who have undergone vitrectomy 8. Subjects with a history of retinal detachment, congenital disease, or treatment and/or surgical history for retinal detachment 9. Subjects with scarring, fibrosis, or atrophy involving the center of the fovea of the study eye 10. Subjects with choroidal neovascularization in the study eye due to causes other than nAMD (however, polypoidal choroidal vasculopathy (PCV) can be enrolled)